AFTER CONSIDERING THE EFFICACY AND SAFETY OF TREMFYA® FOR YOUR COMMERCIALLY INSURED ADULT PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA) EXPERIENCE

COMMERCIAL COVERAGE AS STRONG AS HUMIRA® (adalimumab)—NO STEP EDIT REQUIRED*†

When commercial insurance coverage is delayed >5 business days or denied, TREMFYA withMe offers eligible patients TREMFYA® (guselkumab) at no cost until their commercial insurance covers the medication. See program requirements.

The information provided does not imply comparable safety or efficacy between products and only represents access information. Humira is a registered trademark of AbbVie Inc. Please refer to each product's prescribing information for indication(s), recommended dosing, and administration.

When you choose TREMFYA®, different patient-support programs may help patients get TREMFYA®, depending on their coverage. Patients with government insurance may not have coverage for TREMFYA®. Learn more about specific patient-support programs and eligibility requirements.

Collected in July 2022 and subject to change. This information does not provide advice or guarantee coverage or payment. Legal requirements and plan information can be updated frequently. We strongly recommend contacting the plan for more information about current coverage, restrictions, or prerequisites that may apply.

Source: Managed Markets Insight & Technology, LLC™, a trademark of MMIT, as of July 2022.

LOCAL COVERAGE OPTIONS FOR TREMFYA® (guselkumab)

Explore TREMFYA® coverage options in your area

TREMFYA® coverage has changed in many regions—see where it has preferred first-line access without biologic step edits* by entering a ZIP code below.

*Requiring no step edits indicates a drug will be given first-line biologic access and will not require stepping through other biologic therapies.